Clinical TrialJul 9, 2026, 04:13 PM
CervoMed Completes Enrollment in Phase 2a Study for FTD Drug
AI Summary
CervoMed Inc. announced the completion of enrollment in its Phase 2a study of neflamapimod for the treatment of nonfluent variant primary progressive aphasia (nfvPPA), a type of frontotemporal dementia (FTD). Interim biomarker data from the study is slated for presentation at the 19th CTAD Conference in November 2026, with initial clinical data anticipated in Q1 2027. The company highlighted recent preclinical data supporting neflamapimod's mechanism and its Orphan Drug Designation for FTD from the US FDA in 2024.
Key Highlights
- CervoMed completed enrollment in its Phase 2a study of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA).
- Interim biomarker data from the study will be presented at the 19th CTAD Conference in November 2026.
- First clinical data from the Phase 2a study is expected in the first quarter of 2027.
- The Phase 2a study enrolled 25 participants.
- Neflamapimod received Orphan Drug Designation from the US FDA for FTD in 2024.
- Recent preclinical data in Nature Neuroscience supports p38α inhibition as a therapeutic approach for FTD.
Price Impact
More from CRVO